Effect of N-acetyl cysteine on Parkinson’s disease
Phase 3
- Conditions
- Parkinson's disease.Parkinson's disease
- Registration Number
- IRCT20181006041247N1
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patient's informed consent
No brain surgery in the patient's post medical history
Exclusion Criteria
having brain surgery within a year before starting the treatment period
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The quality of the patient's movement skills and intellectual function. Timepoint: Before and after the invention (one year). Method of measurement: Filling the Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire according to the patient's interview and examining.;Changes in dopaminergic areas within the patient's brain. Timepoint: Before and after the invention (one year). Method of measurement: Technetium-99m-Trodat-1 single-photon emission computerized tomography (SPECT).
- Secondary Outcome Measures
Name Time Method